在使用电子烟和可燃香烟时,catecholamine水平
Remy Poudel1, Shen Li1, Haoyun Hong1
1American Heart Association, Dallas, United States.
Tobacco induced diseases
|August 15, 2024
概括
电子烟和香烟的使用都会增加尿路甲基荷兰胺,这是关键的压力激素. 这些发现表明,甲醇胺可以作为烟草相关危害的生物标志物.
科学领域:
- 心血管生理学心血管生理学
- 环境健康 环境健康
- 生物化学 生物化学
背景情况:
- 众所周知,包括电子烟在内的烟草制品中的尼古丁会增加甲醇胺,造成心血管风险.
- 有限的研究存在于电子烟对甲基荷胺水平的具体影响.
- 提升的甲基醇胺可以解释与电子烟使用相关的不良心血管影响.
研究的目的:
- 调查电子烟和传统香烟使用对尿中甲醇胺和代谢物水平的急性影响.
- 将这些效应与没有吸烟的对照组进行比较.
主要方法:
- 一项观察性队列研究,涉及健康的成年人 (21-45岁),他们目前是电子烟使用者,吸烟者或非烟草使用者.
- 尿样是在接触电子烟或香烟之前和暴露后1个小时和2个小时收集的.
- 使用超高性能液体染色学分析尿中类甲醇胺和代谢物.
主要成果:
- 与非吸烟者相比,吸烟者表现出较低的上腺素,血清素和上腺素代谢物的基线水平.
- 电子香烟和香烟的使用都导致尿路中诺亚上腺素,多巴胺和上腺素代谢物在使用后1小时显著升高.
- 可燃性香烟的使用特别与尿路中诺亚上腺素和多巴胺水平的增加有关.
结论:
- 电子烟和传统香烟的使用与尿路甲基荷胺或其代谢物增加有关.
- 卡特霍胺具有作为评估烟草使用相关危害的生物标志物的潜力.
- 这些发现值得烟草监管科学家在未来的研究工作中考虑.
更多相关视频
10:44Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
11.5K
08:39Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies
Published on: August 25, 2018
25.4K
相关概念视频
Stimulants
174
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
174
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Adrenergic Agonists: Mixed-Action Agents
691
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
691
Adrenergic Neurons: Neurotransmission
3.5K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.5K
Adrenergic Agonists: Direct-Acting Agents
1.4K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.4K
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
